Enhanced thrombin generation and reduced intact protein S in processed solvent detergent plasma

Thrombosis Research

Volumn 135, Issue 1, 2015, Pages 167-174

  Pitkänen, Hanna ^a   Jouppila, Annukka ^a   Mowinckel, Marie Christine ^b,c   Lemponen, Marja ^d   Patiwael, Sanne ^e   Sandset, Per Morten ^b,c   Lassila, Riitta ^d   Brinkman, Herm Jan M ^e  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF HELSINKI   (Finland)

^e SANQUIN RESEARCH   (Netherlands)

Author keywords

Fibrinolysis; Plasma transfusion; Protein S; S D treated plasma; Thrombin generation

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; FIBRIN; PLASMA SUBSTITUTE; PROTEIN S; SOLVENT DETERGENT TREATED PLASMA; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; COAGULATING AGENT; DETERGENT; SOLVENT;

ARTICLE; BLOOD CLOTTING TIME; EUGLOBULIN LYSIS TEST; FIBRIN CLOT; FIBRIN FORMATION; FIBRINOLYSIS; HEMOSTASIS; MEMBRANE MICROPARTICLE; PARTIAL THROMBOPLASTIN TIME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTHROMBIN TIME; SOLID PHASE EXTRACTION; THROMBOELASTOGRAPHY; BLOOD CLOTTING; CHEMISTRY; HUMAN;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; COAGULANTS; DETERGENTS; FIBRIN; FIBRINOLYSIS; HEMOSTASIS; HUMANS; PHENOTYPE; PROTEIN S; SOLVENTS; THROMBELASTOGRAPHY; THROMBIN; TRANEXAMIC ACID;

EID: 84922432354     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2014.10.020     Document Type: Article

References (23)

1. J. Bertolini, N. Goss, and J. Curling Production of Plasma Proteins for Therapeutic Use 1st ed. 2013 Wiley Hoboken, New Jersey, USA
2. U. Salge-Bartels, S. Breitner-Ruddock, A. Hunfeld, R. Seitz, and M. Heiden Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe? Transfus Med 16 2006 266 275
3. P. Hellstern, and B.G. Solheim The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma Transfus Med Hemother 38 2011 65 70
4. A.S. Lawrie, L. Green, M.T. Canciani, I.J. Mackie, F. Peyvandi, and M.A. Scully The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables Vox Sang 99 2010 232 238
5. Food and Drug Administration Octaplas, Pooled Plasma (Human), Solvent/Detergent Treated. Highlights of prescribing information Available at: http://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/licensedproductsblas/ucm336161.pdf 2013 [Accessed 01/27, 2014]
6. I. Dienava-Verdoold, M.R. Marchetti, L.C. te Boome, L. Russo, A. Falanga, and H.R. Koene Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies Thromb Haemost 107 2012 468 476
7. A. Dahm, Vlieg A. Van Hylckama, B. Bendz, F. Rosendaal, R.M. Bertina, and P.M. Sandset Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis Blood 101 2003 4387 4392
8. H.C. Hemker, P. Giesen, R. AlDieri, V. Regnault, E. de Smed, and R. Wagenvoord The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability Pathophysiol Haemost Thromb 32 2002 249 253
9. S.E. Schols, M.A. Feijge, M.D. Lance, K. Hamulyak, H. ten Cate, and J.W. Heemskerk Effects of plasma dilution on tissue-factor-induced thrombin generation and thromboelastography: partly compensating role of platelets Transfusion 48 2008 2384 2394
10. R. Wesselschmidt, K. Likert, T. Girard, T.C. Wun, and G.J. Broze Jr. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa Blood 79 1992 2004 2010
11. M. Dashty, M. Motazacker, J. Levels, M. Vries, M. Mahmoudi, and M. Peppelenbosch Proteome of human plasma very low-density lipoprotein and low-density lipoprotein exhibits a link with coagulation and lipid metabolism Thromb Haemost 111 2014 518 530
12. H.J. Brinkman, K. Mertens, and J.A. van Mourik Proteolytic cleavage of protein S during the hemostatic response J Thromb Haemost 3 2005 2712 2720
13. B. Dahlback Advances in understanding pathogenic mechanisms of thrombophilic disorders Blood 112 2008 19 27
14. M. Takeyama, K. Nogami, E.L. Saenko, T. Soeda, K. Nishiya, and K. Ogiwara Protein S down-regulates factor Xase activity independent of activated protein C: specific binding of factor VIII(a) to protein S inhibits interactions with factor IXa Br J Haematol 143 2008 Nov 409 420
15. M.J. Heeb, D. Prashun, J.H. Griffin, and B.N. Bouma Plasma protein S contains zinc essential for efficient activated protein C-independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor FASEB J 23 2009 2244 2253
16. T.M. Hackeng, and J. Rosing Protein S as cofactor for TFPI Arterioscler Thromb Vasc Biol 29 2009 2015 2020
17. J.B. Holcomb, and S. Pati Optimal trauma resuscitation with plasma as the primary resuscitative fluid: the surgeon's perspective Hematology 2013 2013 656 659
18. L.M. McDaniel, E.W. Etchill, J.S. Raval, and M.D. Neal State of the art: massive transfusion Transfus Med 24 2014 138 144
19. L.M. Williamson, C.A. Llewelyn, N.C. Fisher, J.P. Allain, M.C. Bellamy, and T.P. Baglin A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation Transfusion 39 1999 1227 1234
20. H. Haubelt, M. Blome, A.H. Kiessling, F. Isgro, J. Bach, and W. Saggau Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery Vox Sang 82 2002 9 14
21. J. de Jonge, T.H. Groenland, H.J. Metselaar, J.N. IJzermans, H.H. van Vliet, and L. Visser Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP) Anesth Analg 94 2002 1127 1131
22. J.J. Magner, K.J. Crowley, and J.F. Boylan Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas) J Cardiothorac Vasc Anesth 21 2007 410 413
23. S.A. Kozek-Langenecker, A. Afshari, P. Albaladejo, C.A. Santullano, E. De Robertis, and D.C. Filipescu Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology Eur J Anaesthesiol 30 2013 270 382